Clinical Laserthermia Systems AB Class B (DE:LS60)
FRANKFURT:LS60
LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.19 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€10.16M
Enterprise Value€83.07M
Total Cash (Recent Filing)€21.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€3.49M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue / Installed BaseThe firm's business model includes capital equipment sales plus recurring consumables, software and service revenue tied to installed systems. This installed-base dynamic supports durable repeat purchases and revenue visibility over time, improving long-term margin leverage if clinical adoption grows.
Low Financial LeverageEffectively zero debt and sizable equity provide financial flexibility while the company scales commercial efforts. Low leverage reduces insolvency risk during extended cash burn, enabling funding via equity or partnerships without immediate debt-servicing pressure, a durable strength for early-stage medtech.
Specialized, Structural Market FitThe company targets minimally invasive tumor ablation with an image-guided laser platform and disposables, aligning with structural healthcare trends toward less invasive therapies. Specialized device-plus-consumable model can create clinical stickiness and differentiated workflow advantages over time.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow forces dependence on external financing or reserves. Even with some improvement, ongoing burn limits runway for commercialization and R&D, risks dilution from equity raises and constrains sustainable investment in sales and regulatory initiatives.
Deep, Structural UnprofitabilityNegative gross margins indicate unit economics that don't cover direct costs, not just overhead. Structural unprofitability undermines scalability: unless pricing, cost of disposables, or utilization materially improves, the business cannot convert revenue growth into sustainable profits.
Small, Volatile And Declining RevenueDeclining and volatile top-line curtails operating leverage and makes recurring-revenue potential uncertain. Small revenue base limits ability to absorb fixed costs, slows margin recovery and heightens execution risk in commercial rollouts over the coming months.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.19 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €10.16M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is Aug 14, 2026 which is in 66 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on May 12, 2026. The company reported -€0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.022.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 64.835%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Founded in 2006 and based in Lund, Sweden, Clinical Laserthermia Systems AB (publ) specializes in crafting therapeutic instruments for treating diseased tissues, marketed under their TRANBERG brand. A core offering is the TRANBERG thermal therapy system, engineered to precisely deliver laser energy for heating targeted tissue. Their product range also features a mobile laser unit, an essential control component that operates at a 1064-nanometer wavelength, providing flexible options for treatment management. Additionally, the company supplies a variety of laser applicators in different gauges, alongside advanced devices for monitoring both temperature and the treatment's progress.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―